Occudo Quantitative Strategies LP Buys Shares of 10,109 ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Occudo Quantitative Strategies LP bought a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,109 shares of the company’s stock, valued at approximately $155,000.

Several other hedge funds have also recently added to or reduced their stakes in CLPT. R Squared Ltd acquired a new stake in shares of ClearPoint Neuro during the fourth quarter worth about $32,000. AlphaQuest LLC acquired a new stake in shares of ClearPoint Neuro during the fourth quarter worth about $80,000. Barclays PLC raised its position in shares of ClearPoint Neuro by 24.3% during the third quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after purchasing an additional 1,109 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of ClearPoint Neuro during the fourth quarter worth about $93,000. Finally, JPMorgan Chase & Co. raised its position in shares of ClearPoint Neuro by 58.7% during the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock worth $110,000 after purchasing an additional 3,612 shares during the period. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Stock Performance

NASDAQ:CLPT opened at $13.18 on Friday. The company has a market cap of $368.90 million, a PE ratio of -19.10 and a beta of 1.03. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22. The stock has a 50-day simple moving average of $12.87 and a 200 day simple moving average of $14.23.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.07). The firm had revenue of $8.49 million for the quarter, compared to the consensus estimate of $8.21 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. On average, research analysts predict that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. B. Riley raised their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Lake Street Capital raised their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st. Finally, Stifel Nicolaus increased their price objective on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.